
Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

